Salesforce vs. Figma: Evaluating the Better High-Growth Software Stock to Buy in 2026

Salesforce generated FY2026 revenue of $41.5B (+9.6%), net income of $7.5B and $14.4B of free cash flow, supporting the article's preference for the profitable CRM leader over Figma. Figma grew FY2025 revenue 41% to $1.1B and Q2 revenue 48% to $370.1M, while raising full-year guidance, but posted a $1.3B annual net loss and a $112.2M Q2 loss. Salesforce trades at 14.9x forward P/E and 4.9x sales versus Figma at 66.2x and 10.0x, respectively; the article cites Salesforce's Sept. 15 Koa AI launch and proprietary data scale as additional advantages.

Analysis

The investable distinction is not simply growth versus value: CRM's installed workflow footprint gives it a lower-cost distribution channel for AI monetization, while FIG must prove that usage-based design credits expand wallet share rather than merely repackage existing seats. If agent deployments increase demand for clean customer/workflow data, CRM can lift net retention and attach rates across Data Cloud, Service and platform products; MSFT is the principal competitive risk because Copilot is bundled into an already-owned productivity stack. The claimed AI product differentiation should not be capitalized into estimates until management discloses paid-agent adoption, incremental infrastructure cost, and churn/renewal behavior.

FIG's reported cash generation is economically far weaker than headline FCF implies once dilution is treated as a cash-equivalent expense. That makes its valuation unusually sensitive over the next 1-3 quarters to decelerating enterprise seat growth, gross-margin pressure from AI inference, or a secondary/share-unlock overhang; a modest revenue-multiple reset would dominate any benefit from continued high growth. ADBE is the more relevant second-order beneficiary if enterprise procurement responds to AI-design uncertainty by consolidating around an incumbent creative suite, while AMZN benefits only marginally through cloud consumption and faces customer concentration/price-negotiation risk.

Consensus appears too dismissive of CRM's capital-allocation constraint: large AI/data acquisitions can preserve growth but dilute the operating-discipline narrative that supports its multiple. Conversely, the market may be overpricing FIG as a pure AI winner before evidence that automated design expands the category instead of reducing paid human-editor seats. Near term, this is primarily an earnings-quality and valuation-dispersion setup rather than a broad SaaS-beta call; the key catalysts are CRM's next bookings/remaining-performance-obligation update and FIG's net retention, SBC trend, and AI-cost disclosure.

Key Decisions for Investors

• Initiate a 3-6 month long CRM / short FIG dollar-neutral pair only after confirming FIG borrow availability and upcoming lockup/secondary dates. The thesis is multiple compression at FIG offset by CRM AI attach-rate upside; target 15-20% relative outperformance, with a stop if FIG reports accelerating enterprise net retention alongside materially lower SBC dilution or CRM cuts FY billings guidance.
• Add CRM on a post-results pullback rather than chase AI-launch headlines; size for a 6-12 month horizon. Require evidence of durable low-double-digit subscription growth, improving RPO/bookings, and no material deterioration in operating margin from AI infrastructure or acquisition integration; reduce if MSFT-driven competitive losses emerge in large enterprise renewals.
• Avoid treating FIG's reported FCF as a valuation support until fully diluted share-count growth and recurring AI-inference expense are disclosed. Set an alert for sequential gross-margin compression, slowing revenue growth, or SBC remaining disproportionately above operating cash flow; any two signals would support increasing the FIG short leg.
• Monitor ADBE enterprise renewal commentary over the next two reporting cycles as a read-through on whether generative design is consolidating spend with incumbent suites. ADBE strength coupled with weaker FIG expansion would validate the competitive-substitution thesis; do not establish a standalone ADBE position solely on this signal.